Anthony G Johnson

Anthony G Johnson is an experienced leader in the biotechnology and pharmaceutical sectors, currently serving as a Board Member at NanoSyrinx since November 2023 and Chair of the Board of Directors at Outrun Therapeutics since September 2022. Previously, Johnson held the position of President and CEO at Goldfinch Bio from December 2017 to April 2023 and was a Fellow at Homerton College from March 2016 to November 2017. Johnson's extensive background includes senior roles at AstraZeneca as SVP of Early Clinical Development and various board positions, such as Board of Directors member for Cardioxyl Pharmaceuticals and Rgenix. Johnson has contributed to key investments and clinical development strategies throughout a career that also includes a significant tenure at Bristol-Myers Squibb as VP of Discovery Medicine Clinical Pharmacology. Educational qualifications include an MBBS and MD from The University of New South Wales, and an MPH from The University of Queensland, focusing on Epidemiology and Biostatistics.